Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Lysosome-Targeting Chimeras as Clearing Agents for Pretargeted ImmunoSPECT.

Created on 18 Nov 2026

Authors

Samantha Delaney, Charlotte L Denholt, Jacob Madsen, Andreas Kjær, Matthias M Herth, Umberto Maria Battisti

Published in

Bioconjugate chemistry. Volume 37. Issue 11. Pages 2284-2293. Nov 18, 2026.

Abstract

In vivo pretargeting based on the inverse electron-demand Diels-Alder reaction between a trans-cyclooctene (TCO)-modified monoclonal antibody (mAb) and a radiolabeled tetrazine (Tz) is a highly effective approach for reducing radiation burden in nuclear imaging and therapy. However, the large size and slow pharmacokinetics of full-length immunoglobulins greatly hinder their bloodstream clearance. To circumvent this limitation of pretargeting, much effort has been put towards developing masking or clearing agents: molecules designed to be injected prior to the radioligand to rid the bloodstream of excess circulating TCO-mAbs via clearance organs. Yet even with the use of previously established clearing agents, high levels of TCO-mAb still remain in circulation. Moreover, some of these agents could lead to aggregate formation in the lungs or clogs in the bloodstream. Recently, a novel class of cell-surface protein degraders called lysosome-targeting chimeras (LYTACs) have been reported to simultaneously bind hepatocytic-expressed asialoglycoprotein receptor (ASGPR) and a harmful, disease-relevant protein, internalizing the latter for lysosomal degradation. Herein, we present a novel ASGPR-targeted tetrazine-bearing LYTAC  TriGalNAc-Tz (LYTAC-Tz)  as a clearing agent for pretargeting. First, the essential components of the pretargeted system were synthesized: LYTAC-Tz, a TCO-modified variant of the mAb CC49 (TCO-CC49), and an 111In-labeled DOTA-bearing Tz ([111In]In-DOTA-Tz). Then, LYTAC-Tz was evaluated in vivo for its efficacy as a clearing agent for pretargeting in a murine model of colorectal cancer. SPECT-CT images and ex vivo biodistribution data revealed that LYTAC-Tz resulted in lower blood activity levels than control cohorts along with higher tumor-to-blood ratios. Healthy organs boasted low activity levels (excluding the kidneys, which showed uptake due to their rapid excretion of excess radioligand). Ultimately, this work illustrates that LYTAC-Tzs are effective clearing agents and could be beneficial for reducing radiotoxicity in pretargeted systems.

PMID:
43046848
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement